Please assess the completion status of the following clinical trial:

Trial Title: Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with type 1 diabetes mellitus more than one year~* Current treatment: basal (once daily at bedtime) - bolus (three times a day just before main meals) regimen only for at least 12 weeks using a long-acting insulin analogue excluding insulin detemir or intermediate-acting insulin as a basal insulin and NovoRapid® as bolus insulin (a brand of basal insulin preparation has not been changed in the preceding 12 weeks)~* HbA1c below 10.0%~* Body Mass Index (BMI) below 30.0 kg/m\^2~Exclusion Criteria:~* Known hypoglycaemia unawareness or recurrent major hypoglycaemia~* Current treatment with total insulin dose of more than 100 U or IU/day~* Current treatment or expected to start treatment with systemic corticosteroid

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SIBA (Type: EXPERIMENTAL): None
- Insulin Detemir (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).